Dr. Reddy's
Dr. Reddy's has appeared in 7 distinct RetailIntel stories between May 2026 and Sep 2026, most often under retail brand, retail company and omni channel and most frequently linked to Mumbai, New Delhi and Delhi.
Latest: Novo Nordisk India is pushing to advance Wegovy from a potential 2026 launch as Eli Lilly targets a 2025 Mounjaro introduction (27 Sep 2026). Earlier, delhi High Court ordered Sun Pharma to seek approval before launching oral semaglutide amid Novo Nordisk’s patent suit (11 Aug 2026). Earlier, HDFC Securities expects uneven but normalising Indian consumer demand in FY27, supported by premiumisation, modern trade and e-commerce (23 Jul 2026).
Key figures reported: 2026 (27 Sep 2026); 2025 (27 Sep 2026); two months (27 Sep 2026); ₹46 crore generic semaglutide injectable sales in July (11 Aug 2026).
Brands most often mentioned alongside Dr. Reddy's: Sun Pharma, Cipla, Eli Lilly, Novo Nordisk, Pharmarack, Torrent Pharma.
Most-cited sources on Dr. Reddy's: Business Standard (via Wayback) (1 story), ET Retail (1 story) and ET Small Business (1 story).
- Stories on record: 7
- First seen 12 May 2026 · Latest 27 Sep 2026
- Themes: retail brand, retail company, omni channel
- Cities: Mumbai, New Delhi, Delhi
- Sources cited above: 27 Sep 2026 · 11 Aug 2026 · 23 Jul 2026
Latest signals mentioning Dr. Reddy's
- Resurfacing a December 2024 move: Novo Nordisk India pushed for earlier Wegovy launch as Lilly prepared Mounjaro entry
- Delhi HC requires Sun Pharma to seek clearance before semaglutide launch
- HDFC Securities sees FY27 consumer recovery, but input volatility clouds margins
- Clinikally goes omnichannel with first Gurugram experience centre, eyes 12-15 stores by mid-2027
- Semaglutide channel chokes on Rs 100cr excess stock as April generic rush fades
- CDSCO bars cosmetic injectables, squeezing India's aesthetic clinic chains
- Thomas Cook Q4FY26: Revenue slips 10%, profit down 40% as travel demand cools